ADDF STATEMENT ON GANTENERUMAB DATA PRESENTED AT CTAD ...Middle East

PR Newswire - Economy
ADDF STATEMENT ON GANTENERUMAB DATA PRESENTED AT CTAD
Different results for two amyloid-clearing antibody drugs reinforce need to advance robust, diverse pipeline for Alzheimer's disease SAN FRANCISCO, Nov. 30, 2022 /PRNewswire/ -- The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer's...

Hence then, the article about addf statement on gantenerumab data presented at ctad was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( ADDF STATEMENT ON GANTENERUMAB DATA PRESENTED AT CTAD )

Apple Storegoogle play

Last updated :

Also on site :



Latest News
before 8 hours & 42 minute
before 10 hours & 29 minute